Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Britten

Showing results (71-80 of 101) with videos related to

Pageof 11
Sort By:
Blood|August 26, 2006
Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell linesThomas C Wehler, Marion Nonn, Britta Brandt, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 10, 2015
Generation of TCR-engineered T cells and their use to control the performance of T cell assaysNicole Bidmon, Sebastian Attig, Richard Rae, et al.
European Journal of Cancer (Oxford, England : 1990)|January 27, 2009
Improving the efficacy of cancer immunotherapyJ Copier, A G Dalgleish, C M Britten, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2007
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Sylvia Janetzki, Katherine S Panageas, Leah Ben-Porat, et al.
Journal of Translational Medicine|September 21, 2011
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discoveryDavide Bedognetti, James M Balwit, Ena Wang, et al.
Methods in Molecular Biology (Clifton, N.J.)|December 18, 2016
The European Regulatory Environment of RNA-Based VaccinesThomas Hinz, Kajo Kallen, Cedrik M Britten, et al.
Blood|August 31, 2006
Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantationRalf G Meyer, Cedrik M Britten, Daniela Wehler, et al.
Cancer Immunology, Immunotherapy : CII|November 7, 2009
Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cellsSylvia Janetzki, L Price, C M Britten, et al.
Cancer Immunology, Immunotherapy : CII|April 10, 2015
Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clustersCécile Gouttefangeas, Cliburn Chan, Sebastian Attig, et al.
Journal of Immunological Methods|April 24, 2018
Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performanceNicole Bidmon, Sonja Kind, Marij J P Welters, et al.
Pageof 11

Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
Blood|August 26, 2006
Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell linesThomas C Wehler, Marion Nonn, Britta Brandt, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 10, 2015
Generation of TCR-engineered T cells and their use to control the performance of T cell assaysNicole Bidmon, Sebastian Attig, Richard Rae, et al.
European Journal of Cancer (Oxford, England : 1990)|January 27, 2009
Improving the efficacy of cancer immunotherapyJ Copier, A G Dalgleish, C M Britten, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2007
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Sylvia Janetzki, Katherine S Panageas, Leah Ben-Porat, et al.
Journal of Translational Medicine|September 21, 2011
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discoveryDavide Bedognetti, James M Balwit, Ena Wang, et al.
Methods in Molecular Biology (Clifton, N.J.)|December 18, 2016
The European Regulatory Environment of RNA-Based VaccinesThomas Hinz, Kajo Kallen, Cedrik M Britten, et al.
Blood|August 31, 2006
Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantationRalf G Meyer, Cedrik M Britten, Daniela Wehler, et al.
Cancer Immunology, Immunotherapy : CII|November 7, 2009
Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cellsSylvia Janetzki, L Price, C M Britten, et al.
Cancer Immunology, Immunotherapy : CII|April 10, 2015
Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clustersCécile Gouttefangeas, Cliburn Chan, Sebastian Attig, et al.
Journal of Immunological Methods|April 24, 2018
Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performanceNicole Bidmon, Sonja Kind, Marij J P Welters, et al.
Pageof 11